NASDAQHealth CareBiotechnologySnapshot 2026-07-31
Reading IONS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Total revenue grows by about 20% year over year: revenue growth guidance mid: +115% vs 20%.
View ThesisRevenue is contracting — down about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskIonis Pharmaceuticals must increase sales of its products to justify its current price. Recent revenue grew 56% year over year, and the last quarter beat expectations. It trades at 10× price-to-sales, above the peer median of 9×. If Ionis cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 34% above where it trades. This read is provisional.
Trailing returns as of 2026-07-31. IONS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 25 analysts currently covering IONS (as of Jul 2026).
Based on 11 Wall Street analysts offering 12-month price targets for IONS in the last 4 months.
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-08-01. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Threatens: Increase DAWNZERA product sales to $110-120M
Phase 3 setback impacts DAWNZERA sales expectations.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $51.77
The last 12 months of price, then the range of analyst 12-month targets from today’s $51.77.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Increase TRYNGOLZA peak net sales to >$2B
Missed trial endpoint impacts TRYNGOLZA sales potential.
Advances: Leverage strategic partnership with GSK for bepirovirsen development
Advances partnership with GSK for bepirovirsen development.
Threatens: Increase total revenue by 20% year over year
Price target cut indicates potential revenue growth concerns.
Threatens: Increase TRYNGOLZA peak net sales to >$2B
Trial failure impacts TRYNGOLZA sales potential.
Price target cut indicates potential revenue concerns.
BofA's price target cut reflects negative sentiment on Ionis.
TD Cowen's target cut suggests reduced confidence in Ionis.
